A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension.

Trial Profile

A Multi-center, Double-blind, Randomized, Placebo- and Active-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of 10 mg of ACT-280778 in Patients With Mild to Moderate Essential Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2014

At a glance

  • Drugs ACT 280778 (Primary) ; Amlodipine
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms REDUCE-1
  • Most Recent Events

    • 09 Mar 2013 Primary endpoint 'Seated-blood-pressure' has not been met.
    • 09 Mar 2013 Primary endpoint 'Diastolic-blood-pressure' has not been met.
    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top